Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 15/20 | 0.63 |
| ▸ | ATP4B | P51164 | 15/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.63 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.63 |
| ▸ | FASN | P49327 | 1/20 | 0.63 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.63 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.63 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.63 |
| ▸ | ATP1A1 | P05023 | 9/20 | 0.54 |
| ▸ | ATP1B1 | P05026 | 9/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pantoprazole SCHEMBL29463615 | 1.00 | ATP4A (0.63) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| Pantoprazole SCHEMBL29530572 | 1.00 | ATP4A (0.63) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| Pantoprazole SCHEMBL723548 | 1.00 | ATP4A (0.63) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| Pantoprazole SCHEMBL30777582 | 1.00 | ATP4A (0.63) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| Pantoprazole SCHEMBL29466 | 1.00 | ATP4A (0.63) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| Pantoprazole SCHEMBL3179782 | 0.99 | ATP4A (0.62) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| Pantoprazole SCHEMBL289961 | 0.99 | ATP4A (0.62) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| Pantoprazole SCHEMBL1994486 | 0.99 | ATP4A (0.62) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| Pantoprazole SCHEMBL1716779 | 0.99 | ATP4A (0.62) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| Pantoprazole SCHEMBL29001005 | 0.99 | ATP4A (0.62) | ATP4AATP4BCYP2C9CYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1253 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3790536-B1 | NANOCONTAINERS FOR TRANSPORTING NONPOLAR, LIPOPHILIC SUBSTANCES SUCH AS ANTIBIOTICS | KARLSRUHER INST TECHNOLOGIE (DE) | 2026-04-22 | — | — | EP | claimed |
| US-20260069687-A1 | THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | ASTELLAS PHARMA INC (JP) | 2026-03-12 | — | — | US | claimed |
| EP-3503904-B1 | ASCAROSIDE TREATMENT OF EOSINOPHILIC ESOPHAGITIS | CALIFORNIA INST OF TECHN (US) | 2026-01-21 | — | — | EP | claimed |
| EP-3793518-B1 | AN ORAL TABLET FOR TASTE MASKING OF ACTIVE INGREDIENTS COMPRISING NON-DIRECTLY COMPRESSIBLE SUGAR ALCOHOL PARTICLES | FERTIN PHARMA AS (DK) | 2025-03-26 | — | — | EP | claimed |
| EP-4088716-B1 | AN ORAL TABLET FOR INDUCED SALIVA GENERATION | FERTIN PHARMA AS (DK) | 2024-10-16 | — | — | EP | claimed |
| WO-2024189252-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | LAMINAR PHARMACEUTICALS S.A. (ES) | 2024-09-19 | — | — | WO | claimed |
| EP-4340813-B1 | USE OF THYROID HORMONE T4 IN A HIGH VERSATILITY TREATMENT IN PATIENTS TAKING PROTON PUMP INHIBITORS | ALTERGON SA (CH) | 2024-09-04 | — | — | EP | claimed |
| EP-3892734-B1 | SCREENING METHODS AND THERAPEUTIC APPLICATIONS BASED ON BACTERIAL MOTILITY INHIBITION | UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) | 2024-08-28 | — | — | EP | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| EP-3768322-B1 | FORMULATION | GREEN PARK PHARMA UK LTD (GB) | 2024-07-31 | — | — | EP | claimed |
| EP-0934058-A2 | STABLE DRUG FORM FOR ORAL ADMINISTRATION WITH BENZIMIDAZOLE DERIVATIVES AS ACTIVE INGREDIENT AND PROCESS FOR THE PREPARATION THEREOF | Klinge Pharma GmbH (DE) | 1999-08-11 | — | — | EP | claimed |
| WO-1999027917-A1 | MEDICAMENT PREPARATION IN THE FORM OF A TABLET OR PELLET FOR ACID-LABILE ACTIVE SUBSTANCES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1999-06-10 | — | — | WO | claimed |
| WO-1999003453-A1 | NOVEL PHARMACEUTICAL FORMULATION WITH CONTROLLED RELEASE OF ACTIVE SUBSTANCES | LEK, TOVARNA FARMACEVTSKIH IN KEMIC^¿NIH IZDELKOV , D.D. (SI) | 1999-01-28 | — | — | WO | claimed |
| US-5731002-A | ANTISECRETORY | ASTRA AKTIEBOLAG (SE) | 1998-03-24 | — | — | US | claimed |
| WO-1998000114-A2 | STABLE DRUG FORM FOR ORAL ADMINISTRATION WITH BENZIMIDAZOLE DERIVATIVES AS ACTIVE INGREDIENT AND PROCESS FOR THE PREPARATION THEREOF | KLINGE PHARMA GMBH (DE) | 1998-01-08 | — | — | WO | claimed |
| WO-1997029758-A2 | USE OF AZITHROMYCIN AND TINIDAZOLE FOR THE ERADICATION OF HELICOBACTER PYLORI | DOHMEN WERNER (DE) | 1997-08-21 | — | — | WO | claimed |
| EP-0589981-B1 | ORAL-ADMINISTRATION FORMS OF A MEDICAMENT CONTAINING PANTOPRAZOL | BYK GULDEN LOMBERG CHEM FAB (DE) | 1996-10-23 | — | — | EP | claimed |
| EP-0589981-A1 | ORAL-ADMINISTRATION FORMS OF A MEDICAMENT CONTAINING PANTOPRAZOL. | BYK GULDEN LOMBERG CHEM FAB (DE) | 1994-04-06 | — | — | EP | claimed |
| WO-1992022284-A1 | ORAL-ADMINISTRATION FORMS OF A MEDICAMENT CONTAINING PANTOPRAZOL | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1992-12-23 | — | — | WO | claimed |
| EP-0519365-A1 | Compositions for oral administration containing pantoprazole | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1992-12-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069687-A1 | THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | EPCAM, VSIG8, ICAM1 | ATP4A 1040/4885ATP4B 1787/4885CYP2C9 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.